So the farce that is the US drug approvals theatre continues as now Regeneron pulls out of testing advanced suffering COIVD-19 patients due to safety concerns:
https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms-idUSKBN27F2AY
This follows of course the joke of Remdesivir:
https://www.sciencemag.org/news/2020/10/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug
Bar Dexamethasone and proning, and the results therein are not unequivocal, after 8 months we still have nothing to treat advanced sufferers and bear in mind 90% of mortalities have incidents of ARDS associated. What a sorry state of affairs the world is in.
What a shame Mt Sinai and the NIH have been so tardy too during the biggest medical crisis in modern history. REM-L might be the only genuine treatment answer out there and we are stuck here waiting for recruitment, despite the US now having 100,000 cases a day.
Elli Lilly and now Regeneron not treating advanced COIVD-19 sufferers
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.080(7.37%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $10.71M | 9.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 44355 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 28916 | 8 |
View Market Depth
| Last trade - 12.19pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.080 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 2368891 | ||
| Last updated 12.39pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |